With $1.3 billion in funding, the company has established a cGMP manufacturing facility in Waltham, Massachusetts, with a second site under construction in Pittsburgh.
The $22.2 million agreement aims to advance domestic production of monoclonal antibodies to protect against filoviruses such as Ebola and Sudan viruses.
